EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

FIP1L1::PDGFRA Fusion in a Pediatric Patient Presenting With B‐Cell Lymphoblastic Leukemia

Jenna Nunn iD, Bronwyn Williams, David Deambrosis

Genes, Chromosomes and Cancer · 2025

DOI: 10.1002/gcc.70037 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Genes, Chromosomes and Cancer, 2025. Verfasst von Jenna Nunn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Children's Health Queensland Hospital & Health Service, Brisbane, Australia. Hauptthemen laut MEDLINE: mRNA Cleavage and Polyadenylation Factors, Receptor, Platelet-Derived Growth Factor alpha, Oncogene Proteins, Fusion, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 10% of Ph‐Like patients have ABL class gene fusions, which include the FIP1L1::PDGFRA rearrangement. We report a case of a pediatric patient with Ph‐like B‐lymphoblastic leukemia (B‐LL) with a FIP1L1::PDGFRA fusion and their treatment course using a combination of chemotherapy and targeted therapy with imatinib. A 10‐year‐old female presented with lethargy, palpitations, and fevers. She had pancytopenia, no eosinophilia, and flow cytometry consistent with B‐LL. FISH identified a CHIC2 deletion, suggestive of FIP1L1::PDGFRA fusion, confirmed on next‐generation RNA sequencing. The patient commenced targeted therapy with imatinib, which she continued until completion of standard chemotherapy per COG AALL1732. She remains in remission 6 months post‐completion of therapy. B‐ALL with a FIP1L1::PDGFRA fusion is extremely rare, particularly in pediatrics. FIP1L1::PDGFRA rearrangements can be difficult to detect on routine testing and may not always be seen in association with eosinophilia. Identification of FIP1L1::PDGFRA rearrangements is important as they enable treatment with a tyrosine kinase inhibitor, which has significantly improved the overall prognosis for PDGFRA ‐rearranged neoplasms. Prospective studies assessing imatinib dosage, duration, and long‐term safety are warranted in this cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

mRNA Cleavage and Polyadenylation FactorsReceptor, Platelet-Derived Growth Factor alphaOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansFemaleChildImatinib Mesylate

Stichwörter der Autor:innen

B‐LLFIP1L1::PDGFRAFISHRNA‐seqimatinibpediatric

Substanzen

mRNA Cleavage and Polyadenylation FactorsReceptor, Platelet-Derived Growth Factor alphaOncogene Proteins, FusionImatinib MesylateFIP1L1-PDGFRA fusion protein, humanFIP1L1 protein, human

Autor:innen und Institutionen

  • Children's Health Queensland Hospital & Health Service, Brisbane, Australia.
  • The University of Queensland, Brisbane, Australia.
  • Griffith University, Gold Coast, Australia.
  • Pathology Queensland, Brisbane, Australia.

ORCID-Profile: Jenna Nunn

Zitieren

APA

Nunn, J., Williams, B., & Deambrosis, D. (2025). FIP1L1::PDGFRA Fusion in a Pediatric Patient Presenting With B‐Cell Lymphoblastic Leukemia. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70037

Vancouver

Nunn J, Williams B, Deambrosis D. FIP1L1::PDGFRA Fusion in a Pediatric Patient Presenting With B‐Cell Lymphoblastic Leukemia. Genes, Chromosomes and Cancer. 2025. doi:10.1002/gcc.70037

BibTeX
@article{Nunn2025,
  author = {Nunn, Jenna and Williams, Bronwyn and Deambrosis, David},
  title = {FIP1L1::PDGFRA Fusion in a Pediatric Patient Presenting With B‐Cell Lymphoblastic Leukemia},
  journal = {Genes, Chromosomes and Cancer},
  year = {2025},
  doi = {10.1002/gcc.70037}
}
Kostenlos starten →